BioStock: BioInvent reaches milestone for BI-1808

BioInvent has completed the dose escalation part of the phase I/IIa study with the anti-TNFR2 drug candidate BI-1808. Supported by the positive safety and tolerability profile that the company has observed so far, BioInvent will also study the effect of a higher dose with BI-1808 as monotherapy. Also, the company has, in collaboration with CASI Pharmaceuticals, dosed the first patient in China for the phase I clinical trial evaluating BI-1206 for the treatment of non-Hodgkin’s lymphoma.

Read the article about BioInvent at biostock.se:

https://www.biostock.se/en/2022/09/bioinvent-reaches-milestone-for-bi-1808/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/